Karthikeyan Kandavelou, MD
Hematology & Oncology · Middletown, CTNPI 1730316068
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $568 of the $737 with a category attached, or 77.1%. It is spread thinly across 15 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in CT, where the typical reported total is $1,376.
Across 31 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$112
- AstraZeneca$93
- Bristol Myers Squibb$92
- E.r. Squibb & Sons, L.L.C.$87
- Genentech USA, Inc.$61
- Ipsen Biopharmaceuticals, Inc$49
- plus $243 from 9 others
What the payments were for
- Food & beverage$56877%
- Education$16923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 2 | $112 |
| AstraZeneca | 3 | $93 |
| Bristol Myers Squibb | 3 | $92 |
| E.r. Squibb & Sons, L.L.C. | 4 | $87 |
| Genentech USA, Inc. | 3 | $61 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Gilead | 2 | $27 |
| Merck | 2 | $26 |
| GSK | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
How this compares
$737 in reported general payments places this provider in the 40th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 32 | $734,584 |
| CalquenceAcalabrutinib Maleate | 33 | $505,816 |
| IbrancePalbociclib | 29 | $504,339 |
| Lenalidomide | 26 | $345,951 |
| ImbruvicaIbrutinib | 22 | $337,850 |
| PromactaEltrombopag Olamine | 14 | $175,024 |
| XtandiEnzalutamide | 11 | $122,627 |
| Abiraterone Acetate | 63 | $74,811 |
| XareltoRivaroxaban | 69 | $50,438 |
| EliquisApixaban | 44 | $29,323 |
| Enoxaparin Sodium | 14 | $4,608 |
| Acyclovir | 94 | $2,087 |
| Hydroxyurea | 59 | $1,628 |
| Tamoxifen Citrate | 52 | $1,417 |
| Dexamethasone | 40 | $1,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $87 | $734,58432 claims |
| AstraZenecaCalquence | $93 | $505,81633 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $13 | $337,85022 claims |
| Astellas Pharma US IncXtandi | $22 | $122,62711 claims |
| Johnson & JohnsonXarelto | $19 | $50,43869 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Middletown
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Justine RyuOrange$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.